Critical Survey: Pulse Biosciences (NASDAQ:PLSE) versus Beyond Air (NASDAQ:XAIR)

Beyond Air (NASDAQ:XAIR) and Pulse Biosciences (NASDAQ:PLSE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability and dividends.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Beyond Air and Pulse Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beyond Air	0	1	3	1	3.00
Pulse Biosciences	0	0	0	0	0.00

Beyond Air currently has a consensus target price of $3.67, suggesting a potential upside of 1,247.54%. Given Beyond Air’s stronger consensus rating and higher probable upside, research analysts clearly believe Beyond Air is more favorable than Pulse Biosciences.

Profitability

This table compares Beyond Air and Pulse Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Beyond Air	-1,730.00%	-226.01%	-109.75%
Pulse Biosciences	N/A	-96.89%	-74.83%

Insider and Institutional Ownership

31.5% of Beyond Air shares are held by institutional investors. Comparatively, 76.9% of Pulse Biosciences shares are held by institutional investors. 20.1% of Beyond Air shares are held by company insiders. Comparatively, 71.5% of Pulse Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Beyond Air has a beta of 0.16, meaning that its stock price is 84% less volatile than the S&P 500. Comparatively, Pulse Biosciences has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500.

Valuation and Earnings

This table compares Beyond Air and Pulse Biosciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beyond Air	$3.02 million	6.19	-$60.24 million	($1.06)	-0.26
Pulse Biosciences	$700,000.00	1,458.83	-$42.21 million	N/A	N/A

Pulse Biosciences has lower revenue, but higher earnings than Beyond Air.

Summary

Pulse Biosciences beats Beyond Air on 8 of the 13 factors compared between the two stocks.

About Beyond Air

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.

About Pulse Biosciences

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.